评估早期激素疗法在局限性或局部晚期前列腺癌患者中的应用。

Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer.

作者信息

Kaisary A V

机构信息

Department of Urology, Royal Free Hospital, London, UK.

出版信息

Prostate Cancer Prostatic Dis. 2005;8(2):140-51. doi: 10.1038/sj.pcan.4500800.

DOI:10.1038/sj.pcan.4500800

PMID:15852051

Abstract

This article evaluates the use of early hormonal therapy in patients with localised or locally advanced prostate cancer. In patients receiving radiotherapy, an overall survival benefit is proven for adjuvant goserelin ('Zoladex') in locally advanced disease. Adjuvant to radical prostatectomy, castration (goserelin or orchiectomy) has demonstrated an overall survival benefit in patients with lymph node metastases. Survival advantages have not yet been proven with nonsteroidal antiandrogens, but immediate or adjuvant bicalutamide ('Casodex') improves objective progression-free survival in patients with locally advanced disease, with certain quality-of-life advantages over castration.

摘要

本文评估了早期激素疗法在局限性或局部晚期前列腺癌患者中的应用。在接受放疗的患者中，已证实对于局部晚期疾病，辅助使用戈舍瑞林（“诺雷德”）可带来总生存获益。在根治性前列腺切除术后进行辅助治疗时，去势（戈舍瑞林或睾丸切除术）已在有淋巴结转移的患者中显示出总生存获益。非甾体类抗雄激素药物尚未证实有生存优势，但对于局部晚期疾病患者，立即使用或辅助使用比卡鲁胺（“康士得”）可改善客观无进展生存期，且在生活质量方面比去势有一定优势。